www.fgks.org   »   [go: up one dir, main page]

EP1028736A1 - Bovine teat dip - Google Patents

Bovine teat dip

Info

Publication number
EP1028736A1
EP1028736A1 EP97911685A EP97911685A EP1028736A1 EP 1028736 A1 EP1028736 A1 EP 1028736A1 EP 97911685 A EP97911685 A EP 97911685A EP 97911685 A EP97911685 A EP 97911685A EP 1028736 A1 EP1028736 A1 EP 1028736A1
Authority
EP
European Patent Office
Prior art keywords
solution
laureth
carboxylic acid
weight
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97911685A
Other languages
German (de)
French (fr)
Other versions
EP1028736A4 (en
Inventor
David J. Ricketts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1997/018389 external-priority patent/WO1999018978A1/en
Publication of EP1028736A1 publication Critical patent/EP1028736A1/en
Publication of EP1028736A4 publication Critical patent/EP1028736A4/en
Withdrawn legal-status Critical Current

Links

Definitions

  • An iodophor teat dip comprising a solution of a fatty alcohol polyglycol ether carboxylic acid, glycerin, I 2 , I- (or HI) and, a pH buffer.
  • the teat dip reduces the spread of mastitis infection, imparts a smoother teat condition, improves milk let down, and has few discernible long term effects .
  • This invention relates to a new and improved iodophor teat dip containing I : and I- (or HI) , a specific surfactant, and glycerin which is suitable for reducing the spread of mastitis infection, and improving teat appearance and skin condition; this in turn enables faster let down and milk out.
  • present commercial teat dip formulations have been developed to combine desired germicidal properties with suitable emolliency, and include surfactants such as 9 - 12 mole ethoxylated phenols containing I 2 , I- and glycerine.
  • a surfactant of this type used in a teat dip is sold by Norman Fox & Co. under the trade name of NORFOX N-P9, and listed in "McCutcheon' s Emulsifiers and Detergents" , 1989 specifically for use with iodophors .
  • the NORFOX N-P9 formulation tends to cause the teat skin to become chapped, cracked and calloused, which in turn leads to infection, which can provide a mastitis site, and weaken the cow for other infections, delayed milk let down, and bovine discomfort when milking.
  • teat dip is sold as KlenzadeTM Teat Guard, containing a nonyl phenoxypolyethoxy ethanol surfactant having 1% titratable iodine, but this product does not keep a soft teat skin.
  • KlenzadeTM Teat Guard containing a nonyl phenoxypolyethoxy ethanol surfactant having 1% titratable iodine, but this product does not keep a soft teat skin.
  • bovine teat dip formulations have employed an emollient such as lanolin, but these formulations have failed to exhibit the desired characteristics of emolliency.
  • a bovine teat dip formulation which has a suitable capability for dispersing I 2 and I- (or HI) ; does not form toxic or objectionable compounds with I 2 ; improves the teat appearance; reduces teat callousing and cracking; improves milk let down; reduces discomfort when milking; maintains a suitable capability for reducing the spread of mastitis; has a reasonably good phase stable shelf life over a reasonably wide temperature range; and, is inexpensive to formulate.
  • an iodophor teat dip formulation comprising an emulsifier/dispersant of water soluble, nonionic, fatty alcohol polyglycol ether carboxylic acids; glycerin, and the like; effective amounts of I 2 and I- (or HI, and the like) ; and a pH buffer.
  • emulsifier/dispersant of this type is sold by Alcolac Inc.
  • AKYPO m RLM-45 AKYPO tm RLM-100
  • AKYPO tm RLM-130 AKYPO tm RLM-160
  • the preferred composition being AKYPO t RLM-100 (Chemical Abstracts Registry 74349-89-6) .
  • the emulsifier/dispersants function together with the glycerine to impart the necessary emolliency for smooth teats, with reduced cracking, callousing and sores. This lessens the risk of infection sites leading to mastitis, and other diseases.
  • the AKYPO tm RLM emulsifiers/dispersants used in the formulation are laureth/myristic (11 - 17) carboxylic acids, with an HLB (Hydrophilic/Lipophilic Balance) number of about 10 - 16;
  • AKYPO c ⁇ RLM-100 itself has an HLB of 14.8.
  • the formulation may have a small content (e.g., 5%) of stearic acid.
  • Typical formulations comprise I 2 : about 0.45% - 1.3%; HI, or equivalent (e.g., KI , Nal, Cal 2 , etc., and mixtures thereof): sufficient to form about 0.25% -0.3% I-; glycerin, and the like: about 5% - 12.5%; a buffer such as citric acid and/or lactic acid; and, caustic for adjusting the pH to about 4.0 - 5.5, and preferably to about 4.8 - 5.2; emulsifier/dispersant : about 7.5% - 12.5%; and, water: balance, all parts by weight. If the glycerin content is below about 5%, the formulation did not appear effective.
  • HI or equivalent (e.g., KI , Nal, Cal 2 , etc., and mixtures thereof): sufficient to form about 0.25% -0.3% I-; glycerin, and the like: about 5% - 12.5%; a buffer such as citric acid and/or lactic
  • hydroxy equivalents to the preferred glycerine may be used, and include: sorbitol; mannitol; galacticol; 1, 2 , 6-hexanetriol ; non- ionic polyethylene glycol having a molecular weight of from 100 to 800; the propylene and di -propylene glycols; the pentitols such as arabitol; and, mixtures thereof .
  • the emulsifier/dispersant content is below about 7.5%, ⁇ he formulation becomes unstable due to lack of iodine complexing capability, and if the emulsifier/dispersant content is above about 12.5%, no significant improvement was observed.
  • a suitable formulation was produced having a phase- stable shelf life of about two (2) years within an ambient temperature range of about 30°F - 110°F.
  • the formulation may be produced as a concentrate and then diluted with water prior to use.
  • EXAMPLE 1 Using the above formulation, several herds totalling 2,600 dairy cows was treated during a four month period with about 625,000 teat dips. The herd initially had a low mastitis and infection rate, and use of the above formulation neither improved or worsened the condition of the herd. However, there was a significant improvement in teat appearance, such as a smoother teat, with significantly fewer cracks and a consequent lessened opportunity for spreading an infectious disease such as mastitis . Also there was noted a greater improvement in faster let down and onset of milking, indicating reduced irritation of the cow teats. The life span of cows is about three to seven years, and during the period commencing from the four month tests in 1988 to 1994, no significant change in the herd life span was noted.
  • EXAMPLE 2 In a 1994 test, 12 dairy herds of about 200 cows each were treated with the above formulation, and a noticeable improvement in teat condition was observed within about ten (10) days. Fewer cracks, sores, callousing, etc., appeared, resulting in the cow teats being much easier to prepare for milking and a a consequent faster milking operation due to less discomfort.
  • the concentrate was formed with a foamer-thickener to produce a 0.75% I 2 skin wash.
  • the formulation of this invention may be augment other less expensive teat dips to reduce costs.
  • this type of usage about 0.045% by weight of the concentrate is used, the balance being the less expensive teat dip.
  • the concentrate also may be employed to protect the hands when working with food, and when working with food and medical utensils. Also, the diluted concentrate is useful to protect the hands during contact with sanitizing iodine solutions used for example in conjunction with pet shampoos.
  • This concentrate may then be diluted to produce various skin and body care products for use in a carrier such as commercial liquid soaps, sprays, powders, creams, ointments and mixtures thereof to improve skin smoothness, to reduce chapped, scratched or abraded hands, or rashes; as a surgical scrub; as a skin germicide for cuts, dressings, wounds, etc; for acne treatment; for animal and pet shampoos, etc.
  • a carrier such as commercial liquid soaps, sprays, powders, creams, ointments and mixtures thereof to improve skin smoothness, to reduce chapped, scratched or abraded hands, or rashes; as a surgical scrub; as a skin germicide for cuts, dressings, wounds, etc; for acne treatment; for animal and pet shampoos, etc.
  • the formulation of this invention may include germicides, insect repellents, perfumes, moisturizers, antifungal agents, emollients, humectants, defoamers, antibiotics, additional specific soaps, etc.
  • a typical amount of concentrate at the lower concentration level is about 30 ppm, and at the higher concentration level, the I 2 concentration should not exceed about 1.1% by weight.
  • the I ' may be formulated as an ion of Na, K, Mg, Fe, Zn, Mn, Ca, H ⁇ , etc.
  • the teat dip and method of this invention provides a product having good germicidal properties, and which imparts a smoother teat with fewer callouses, roughness, sores and cracking. Use of the formulation thus reduces entry sites for infection and subsequent spreading of disease such as mastitis, and milking is made easier due to less teat irritation.
  • the teat dip formulation of this invention is relatively inexpensive and has a reasonably good shelf life at ambient conditions.
  • the teat concentrate may be used at a greater dilution to reduce costs and still maintain their healthy status.
  • the laureth/myristic surfactant employed in the formulation of this invention may be used in conjunction with I 2 and I " as a concentrate, generally containing: I " : 2% - 16%; I 2 : 3% - 40%; laureth/myristic surfactant: 50% - 95%; and, water: balance, all parts by weight.
  • a preferred concentrate contains: I " : 6.8%; I 2 : 22%; RLMTM100: 66%; and, water: 5.2%, all parts by weight.

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An iodophor teat dip is disclosed comprising a solution of a fatty alcohol polyglycol ether carboxylic acid, glycerin, I2, I- (or HI) and, a pH buffer. The teat dip reduces the spread of mastitis infection, imparts a smoother teat condition, improves milk let down, and has few discernible long term effects.

Description

BOVINE TEAT DIP
An iodophor teat dip is disclosed comprising a solution of a fatty alcohol polyglycol ether carboxylic acid, glycerin, I2, I- (or HI) and, a pH buffer. The teat dip reduces the spread of mastitis infection, imparts a smoother teat condition, improves milk let down, and has few discernible long term effects .
This invention relates to a new and improved iodophor teat dip containing I: and I- (or HI) , a specific surfactant, and glycerin which is suitable for reducing the spread of mastitis infection, and improving teat appearance and skin condition; this in turn enables faster let down and milk out.
Many types of teat dip similar formulations have been employed in the past, and typical examples are found in U.S.
Patents 2,977,315; 3,950,554; 4,049,830 4,258,056; 4,371,517;
4,671,958; 4,678,668; 4,940,702; 5,028,427; 5,175,160;
5,208,257; and, German Patent 2,936,934.
The use of I2 with I- (or HI) which complexes, rather than reacts with the surfactant to produce unwanted and possibly toxic reaction products, is disclosed in U.S. Patents 2,599,140;
2,710,277 and 2,977,315 which describe tamed iodine or iodophor, etc. Also, the use of polyethenoxy detergents and I2 is disclosed in an article by Benjamin Carroll in the Journal of
Bacteriology, 69; 413-417, (1955) . In an attempt to avoid the use of I2 and I (or HI) , the use of bromo-nitro-propanol as the germicide in teat dips is disclosed in U.S. Patent 4,049,830, but this latter formulation is considered to have insufficient germicidal properties compared to using iodine .
Consequently, present commercial teat dip formulations have been developed to combine desired germicidal properties with suitable emolliency, and include surfactants such as 9 - 12 mole ethoxylated phenols containing I2, I- and glycerine.
A surfactant of this type used in a teat dip is sold by Norman Fox & Co. under the trade name of NORFOX N-P9, and listed in "McCutcheon' s Emulsifiers and Detergents" , 1989 specifically for use with iodophors .
However, the NORFOX N-P9 formulation tends to cause the teat skin to become chapped, cracked and calloused, which in turn leads to infection, which can provide a mastitis site, and weaken the cow for other infections, delayed milk let down, and bovine discomfort when milking.
Another type of teat dip is sold as Klenzade™ Teat Guard, containing a nonyl phenoxypolyethoxy ethanol surfactant having 1% titratable iodine, but this product does not keep a soft teat skin. Still other bovine teat dip formulations have employed an emollient such as lanolin, but these formulations have failed to exhibit the desired characteristics of emolliency.
A bovine teat dip formulation is desired which has a suitable capability for dispersing I2 and I- (or HI) ; does not form toxic or objectionable compounds with I2; improves the teat appearance; reduces teat callousing and cracking; improves milk let down; reduces discomfort when milking; maintains a suitable capability for reducing the spread of mastitis; has a reasonably good phase stable shelf life over a reasonably wide temperature range; and, is inexpensive to formulate.
THE INVENTION: According to the invention, an iodophor teat dip formulation is provided comprising an emulsifier/dispersant of water soluble, nonionic, fatty alcohol polyglycol ether carboxylic acids; glycerin, and the like; effective amounts of I2 and I- (or HI, and the like) ; and a pH buffer. A suitable emulsifier/dispersant of this type is sold by Alcolac Inc. under the trade names of AKYPOmRLM-45, AKYPOtmRLM-100 , AKYPOtmRLM-130 and AKYPOtmRLM-160 , and mixtures thereof, the preferred composition being AKYPOtRLM-100 (Chemical Abstracts Registry 74349-89-6) .
As described in "McCutcheon' s Emulsifiers & Detergents", 1989, these AKYPOtmRLM emulsifiers/dispersants are listed for personal care products to improve skin feel, in high electrolyte household and industrial formulae, and as an emulsifier for synthetic latex, but they are not listed for use in teat dip formulations. The entire contents of "McCutcheon' s Emulsifiers & Detergents" 1989 - 1994 are incorporated herein by reference. However, according to the invention, it has been discovered unexpectedly that used in conjunction with appropriate amounts of glycerin, an iodophor such as I2, I- (or HI) and, a pH buffer, these water soluble, emulsifiers/dispersants produce a teat dip having the above requisite properties. An adequate, liquid phase stable life over a wide range of ambient temperatures is obtained and moreover, the emulsifier/dispersant probably complexes the iodine and maintains the iodine in solution; this prevents the iodine from precipitating and forming a separate, solid phase.
Also, the emulsifier/dispersants function together with the glycerine to impart the necessary emolliency for smooth teats, with reduced cracking, callousing and sores. This lessens the risk of infection sites leading to mastitis, and other diseases.
The AKYPOtmRLM emulsifiers/dispersants used in the formulation are laureth/myristic (11 - 17) carboxylic acids, with an HLB (Hydrophilic/Lipophilic Balance) number of about 10 - 16;
AKYPORLM-100 itself has an HLB of 14.8. The formulation may have a small content (e.g., 5%) of stearic acid.
Typical formulations comprise I2: about 0.45% - 1.3%; HI, or equivalent (e.g., KI , Nal, Cal2, etc., and mixtures thereof): sufficient to form about 0.25% -0.3% I-; glycerin, and the like: about 5% - 12.5%; a buffer such as citric acid and/or lactic acid; and, caustic for adjusting the pH to about 4.0 - 5.5, and preferably to about 4.8 - 5.2; emulsifier/dispersant : about 7.5% - 12.5%; and, water: balance, all parts by weight. If the glycerin content is below about 5%, the formulation did not appear effective. Other hydroxy equivalents to the preferred glycerine may be used, and include: sorbitol; mannitol; galacticol; 1, 2 , 6-hexanetriol ; non- ionic polyethylene glycol having a molecular weight of from 100 to 800; the propylene and di -propylene glycols; the pentitols such as arabitol; and, mixtures thereof .
If the emulsifier/dispersant content is below about 7.5%, πhe formulation becomes unstable due to lack of iodine complexing capability, and if the emulsifier/dispersant content is above about 12.5%, no significant improvement was observed.
Using an AKYPOtmRLM-100 emulsifier/dispersant of about 10%; an I2 content of about 1.05%; an I- content of about 0.28%; about 10% glycerin; citric acid to buffer the pH; caustic to obtain a pH range of about 4.8 - 5.2; and the balance water (all parts by weight) , a suitable formulation was produced having a phase- stable shelf life of about two (2) years within an ambient temperature range of about 30°F - 110°F. For a bovine teat dip, the formulation may be produced as a concentrate and then diluted with water prior to use.
EXAMPLE 1. Using the above formulation, several herds totalling 2,600 dairy cows was treated during a four month period with about 625,000 teat dips. The herd initially had a low mastitis and infection rate, and use of the above formulation neither improved or worsened the condition of the herd. However, there was a significant improvement in teat appearance, such as a smoother teat, with significantly fewer cracks and a consequent lessened opportunity for spreading an infectious disease such as mastitis . Also there was noted a greater improvement in faster let down and onset of milking, indicating reduced irritation of the cow teats. The life span of cows is about three to seven years, and during the period commencing from the four month tests in 1988 to 1994, no significant change in the herd life span was noted.
EXAMPLE 2. In a 1994 test, 12 dairy herds of about 200 cows each were treated with the above formulation, and a noticeable improvement in teat condition was observed within about ten (10) days. Fewer cracks, sores, callousing, etc., appeared, resulting in the cow teats being much easier to prepare for milking and a a consequent faster milking operation due to less discomfort.
Also, there was no increase in the somatic (white cell) count, an increase in this cell count being the first sign of a reduced resistance to infectious disease such as mastitis. Additionally, there was a decreased reaction of milker's hands such as chapping, etc., compared to using the NORFOX NP-9 nonyl phenoxy surfactant . In a fourth test, a male subject in his mid-fifties washed the back of one hand with the concentrate of this invention, the other hand being used as a control. The daily treatment was designed to remove burn scar tissue, and after 2 months of washing, a slow but noticeable improvement was observed.
The concentrate was formed with a foamer-thickener to produce a 0.75% I2 skin wash.
Additionally, the formulation of this invention may be augment other less expensive teat dips to reduce costs. In this type of usage, about 0.045% by weight of the concentrate is used, the balance being the less expensive teat dip.
The concentrate also may be employed to protect the hands when working with food, and when working with food and medical utensils. Also, the diluted concentrate is useful to protect the hands during contact with sanitizing iodine solutions used for example in conjunction with pet shampoos.
This concentrate may then be diluted to produce various skin and body care products for use in a carrier such as commercial liquid soaps, sprays, powders, creams, ointments and mixtures thereof to improve skin smoothness, to reduce chapped, scratched or abraded hands, or rashes; as a surgical scrub; as a skin germicide for cuts, dressings, wounds, etc; for acne treatment; for animal and pet shampoos, etc.
For these uses, the formulation of this invention may include germicides, insect repellents, perfumes, moisturizers, antifungal agents, emollients, humectants, defoamers, antibiotics, additional specific soaps, etc.
In the diluted form, such as in liquid soap, ointment, etc., a typical amount of concentrate at the lower concentration level is about 30 ppm, and at the higher concentration level, the I2 concentration should not exceed about 1.1% by weight. The I' may be formulated as an ion of Na, K, Mg, Fe, Zn, Mn, Ca, H~, etc.
While acne itself is not considered a serious disease, it does pose psychological problems, and hence any alleviation of acne and/or associated skin scarring effects would be desirable. The above formulation of this invention was tested daily for various periods of time on three subjects, ranging in age from 14 years (female) - test period 1.5 months (applied with a liquid skin care soap) ; 28 years (male) - test period 1 month (applied as a dilute solution) ; and, 42 years (female) - test period 9 months (applied with a liquid skin care soap) . All three tests resulted in complete acne remission, with mitigation of scarring due to skin peeling. The teat dip and method of this invention provides a product having good germicidal properties, and which imparts a smoother teat with fewer callouses, roughness, sores and cracking. Use of the formulation thus reduces entry sites for infection and subsequent spreading of disease such as mastitis, and milking is made easier due to less teat irritation.
Moreover, the teat dip formulation of this invention is relatively inexpensive and has a reasonably good shelf life at ambient conditions.
It has also been found that once the cow teats have been improved to the point where they are in a healthy condition, the teat concentrate may be used at a greater dilution to reduce costs and still maintain their healthy status.
The laureth/myristic surfactant employed in the formulation of this invention may be used in conjunction with I2 and I" as a concentrate, generally containing: I": 2% - 16%; I2 : 3% - 40%; laureth/myristic surfactant: 50% - 95%; and, water: balance, all parts by weight. A preferred concentrate contains: I": 6.8%; I2 : 22%; RLM™100: 66%; and, water: 5.2%, all parts by weight.

Claims

CLAIMS :
CLAIM 1. A teat dip solution, comprising: a water soluble solution of a non-ionic, laureth (11 - 16) carboxylic acid having an HLB of about 10 - 16: about 7.5% - 12.5%; an effective amount of an iodophor; glycerin, and the like: about 5% - 12.5%; a buffer; an agent for adjusting the solution pH to about 4.0 - 5.5; and, water: balance, all parts by weight.
CLAIM 2. A concentrate solution suitable, by dilution, for skin care and germicide use, comprising: a water soluble solution of a non- ionic, laureth/myristic (11 - 16) carboxylic acid having an HLB of about 10 - 16; about 50% - 95%; I": about 2% - 16%; I2 : 3% - 40%; and, water: balance, all parts by weight.
CLAIM 3. The solution of Claim 2, admixed with a carrier, the concentrate solution comprising from about 30 ppm concentration in the carrier to about 1.1% I2 concentration in the carrier.
CLAIM 4. The solution of Claim 3, comprising: I": about 6.8%; I2: about 22%; laureth/myristic (11 - 16) carboxylic acid: about 66%; and, water: about 5.2%, all parts by weight.
CLAIM 5. The solution of Claim 3, in which the carrier is selected from the class consisting of liquid soaps, sprays, powders, creams, ointments and mixtures thereof.
CLAIM 6. The solution of Claim 3, in which the carrier includes a foamer-thickener .
CLAIM 7. A method for treating acne and scar tissue, comprising applying the solution of Claim 2 to the acne and scar tissue.
CLAIM 8. The solution of Claim 1, comprising: a water soluble _ solution of a laureth/myristic (11 - 16) carboxylic acid having an HLB of about 10 - 16: about 7.5% - 12.5%; an I2 content of about 0.45% - 1.3%; HI, or equivalent: sufficient to form about 0.25% - 0.3% I-; glycerin, and the like: about 5% - 12.5%; a buffer; caustic for adjusting the solution pH to about 4.0 - 5.5; and, water: balance, all parts by weight.
CLAIM 9. The solution of Claim 8, in which the laureth/myristic (11 - 16) carboxylic acid has an HLB of about 14.8 .
CLAIM 10. The solution of Claim 2, in which about 0.045% by weight of the concentrate is emplyed to augment a teat dip.
CLAIM 11. The solution of Claim 8, which contains glycerine, sorbitol, mannitol, galacticol, the propylene and di-propylene glycols, 1 , 2 , 6-hexanetriol , pentitols including arabitol, non- ionic polyethylene glycol having a molecular weight of from 100 - 800, and mixtures thereof.
CLAIM 12. The solution of Claim 8, having a phase stable shelf 5 life of about two years at ambient temperature.
0
CLAIM 13. The solution of Claim 8, comprising a non-ionic, laureth/myristic (11 - 16) carboxylic acid: about 10%; an I2 content of about 0.25% - 0.3%; about 10% glycerin; a pH buffer; caustic to obtain a solution pH range of about 4.0 - 5.5; and, the balance water, all parts by weight.
CLAIM 14. The solution of Claim 8, comprising: laureth/myristic (11 - 16) carboxylic acid with an HLB of 14.8; an I- content of about 0.28%; a buffer of citric or lactic acid; and, caustic to adjust the solution pH to about 4.8 - 5.2 .
CLAIM 15. A method of treatment for teats to reduce the spread of infectious disease, by applying to the teat area a solution, comprising: a water soluble solution of a non-ionic, laureth/myristic (11 -16) carboxylic acid having an HLB of about 10 - 16: about 7.5% - 12.5%; an effective amount of an iodophor; glycerine, and the like: about 5% - 12.5%; a buffer; a caustic for adjusting the solution pH to about 4.0 - 5.5; and, water: balance, all parts by weight.
CLAIM 16. The method of Claim 15, in which the solution comprises a laureth/myristic (11 - 16) carboxylic acid having an HLB of about 10 - 16: about 7.55 - 12.5%; and I2 content of about 0.45% - 1.3%; HI or equivalent: sufficient to form about 0.25% - 0.3%I-; glycerin, and the like: about 5% - 12.5%; a buffer; caustic for adjusting the solution pH to about 4.0 - 5.5; and, water: balance, all parts by weight.
CLAIM 17. The method of Claim 15, in which the laureth/myristic (11 - 16) carboxylic acid has an HLB of about 14.8 .
CLAIM 18. The method of Claim 15, in which the buffer is 5. selected from the class consisting of citric acid, lactic acid and mixtures thereof, and the solution pH is about 4.8 - 5.2 .
CLAIM 19. A teat dip solution, comprising: a water soluble solution of a non-ionic, laureth (11 - 16) carboxylic acid having 0 an HLB of about 10 - 16: about 7.5% - 12.5%; an effective amount of stabilized iodine; glycerin, and the like: about 5% - 12.5%; a buffer; an agent for adjusting the pH to about 4.0 - 5.5; and water: balance, all parts by weight.
5 CLAIM 20. The method of treatment according to Claim 10, comprising applying to the teat area a soluble solution of a nonionic, laureth (11 - 16) carboxylic acid having an HLB of about 10 - 16: about 7.5% - 12.5%; an effective amount of stabilized iodine; glycerine, and the like: about 5% - 12.5%; a buffer; a 0 caustic for adjusting the solution pH to about 4.0 - 5.5; water: balance, all parts by weight.
5
0
EP97911685A 1997-10-14 1997-10-14 Bovine teat dip Withdrawn EP1028736A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/018389 WO1999018978A1 (en) 1996-07-05 1997-10-14 Bovine teat dip

Publications (2)

Publication Number Publication Date
EP1028736A1 true EP1028736A1 (en) 2000-08-23
EP1028736A4 EP1028736A4 (en) 2002-04-03

Family

ID=22261856

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97911685A Withdrawn EP1028736A4 (en) 1997-10-14 1997-10-14 Bovine teat dip

Country Status (2)

Country Link
EP (1) EP1028736A4 (en)
AU (1) AU4900097A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913859B1 (en) 2013-03-15 2018-03-13 Webco Chemical Corporation Dairy animal teat disinfectant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9918978A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913859B1 (en) 2013-03-15 2018-03-13 Webco Chemical Corporation Dairy animal teat disinfectant
US11766452B2 (en) 2013-03-15 2023-09-26 Webco Chemical Corporation Compositions of and methods for dairy animal teat dip

Also Published As

Publication number Publication date
AU4900097A (en) 1999-05-03
EP1028736A4 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
US5720984A (en) Bovine teat dip
US5534266A (en) Bovine teat dip
CA2175179C (en) Non-aqueous emollient iodophor formulations
US5716611A (en) Emollient antimicrobial formulations containing povidone iodine
CA2151774C (en) Skin disinfecting formulations
US3950554A (en) Treatment of mastitis in bovine udders
US20070249712A1 (en) Peracetic teat dip
MXPA06012442A (en) Therapeutic antimicrobial compositions and methods.
US20060177518A1 (en) Peracetic teat dip
US5137718A (en) Infection fighting composition for topical application
CA2535004C (en) Topical veterinary compositions and methods for the treatment and prevention of infection
AU769364B2 (en) Iodine containing antimicrobial compositions for mastitis control
JP2556973B2 (en) Antiseptic composition
EP1322157A2 (en) Antimicrobial compositions formulated for use in cold temperature conditions and methods of use thereof
US4067967A (en) Composition for topical application to humans and animals
CA2208610C (en) Bovine teat dip
EP1028736A1 (en) Bovine teat dip
AU2006235798A1 (en) Topical composition
CN111787903A (en) Disinfectant composition
WO2005048709A1 (en) Use of panthenol in teat dip/spray preparations
Hemling et al. Evaluation of bovine teat condition in commercial dairy herds: 6. Teat condition-prevention and cure through teat dips
AU5660786A (en) Antiseptic compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020218

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 33/36 A, 7A 61K 31/19 B, 7A 61K 31/045 B, 7A 61K 33/18 B, 7A 61K 9/00 B

17Q First examination report despatched

Effective date: 20020624

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060502